Exagen Inc. (NASDAQ: XGN) reported Q3 EPS of ($0.31), $0.15 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $17.24 million versus the consensus estimate of $16.9 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.